Process for preparing stealth nanoparticles

US10967039B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10967039-B2
Application numberUS-201414894495-A
CountryUS
Kind codeB2
Filing dateMay 28, 2014
Priority dateMay 28, 2013
Publication dateApr 6, 2021
Grant dateApr 6, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.

First claim

Opening claim text (preview).

The invention claimed is: 1. A process for the preparation of nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion, wherein said miniemulsion comprises: (i) at least one alkyl cyanoacrylate monomer; (ii) at least two different polyalkylene glycols independently selected from the group consisting of polyethylene glycols (PEG), polypropylene glycols (PPG), and copolymers thereof; and (iii) optionally one or more active agents, wherein at least one of said polyalkylene glycols initiates the single step anionic polymerisation reaction. 2. The process for the preparation of nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer in claim 1 , wherein at least one of said polyalkylene glycols is covalently attached to a targeting moiety. 3. The process as claimed in claim 1 , wherein said miniemulsion is prepared by the addition of said at least two polyalkylene glycols to an oil-in water miniemulsion comprising said at least one alkyl cyanoacrylate monomer and optionally said one or more active agents. 4. The process as claimed in claim 3 , wherein said nanoparticles are stealth nanoparticles. 5. The process as claimed in claim 3 , wherein said miniemulsion further comprises a radically polymerisable crosslinker selected from the group consisting of an anhydride and an acrylate. 6. The process as claimed in claim 3 , wherein said at least one alkyl cyanoacrylate monomer is selected from the group consisting of ethyl cyanoacrylate, butyl cyanoacrylate, isohexyl cyanoacrylate, octyl cyanoacrylate and derivatives and mixtures thereof. 7. The process as claimed in claim 3 , wherein at least one of the polyalkylene glycols is a polyethylene glycol, optionally further comprising a hydrophobic component. 8. The process of claim 7 , wherein at least one of the polyethylene glycols is a block copolymer of a polyethylene glycol block and polypropylene glycol block and wherein said copolymer comprises a hydroxy or amino end group attached to the polypropylene glycol block. 9. The process of claim 3 wherein the targeting moieties are selected from the group consisting of peptides, miniproteins, antibody fragments, affibody molecules, nanobodies and aptamers. 10. The process of claim 3 , wherein the targeting moieties are selected from the group consisting of peptides, antibody fragments, affibody molecules, nanobodies and aptamers. 11. The process of claim 3 wherein the active agent is a therapeutic agent selected from the group consisting of docetaxel, cabazitaxel, paclitaxel, 5-fluorouracil, sorafenib, AMG900, temsirolimus or everolimus. 12. The process of claim 3 wherein the active agent is selected from the group consisting of carboplatin, oxaliplatin, picoplatin, tetraplatin, satraplatin, cisplatin, platinum-DACH and ormaplatin. 13. The process of claim 3 wherein the active agent is an imaging agent selected from the group consisting of metals, metal salts, near infrared dyes, fluorescent dyes, PET/SPECT chelating agents, agents suitable for MRI or Raman spectroscopy and radiopharmaceutical s.

Assignees

Inventors

Classifications

  • obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides · CPC title

  • on to polyethers, polyoxymethylenes or polyacetals {(C08F283/004 takes precedence)} · CPC title

  • Ion exchange resins, e.g. polystyrene sulfonic acid resin · CPC title

  • A61K38/06Primary

    Tripeptides · CPC title

  • Alpha-cyano-acrylic acid butyl ester · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10967039B2 cover?
A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.
Who is the assignee on this patent?
Sintef Tto As
What technology area does this patent fall under?
Primary CPC classification A61K38/06. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).